Stanford ...has Rosemarie and other names of interest on that patent and now just filed a new one with Novartis
Justia Patents Rosemarie H. DeKruyff Inventions, Patents and Patent Applications
Patents by Inventor Rosemarie H. DeKruyff Rosemarie H. DeKruyff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF Publication number: 20170198041 Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders. Type: Application Filed: February 14, 2017 Publication date: July 13, 2017 Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF Publication number: 20170190777 Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders. Type: Application Filed: March 17, 2017 Publication date: July 6, 2017 Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu BLOCKADE OF RGMb FOR REDUCING TRANSPLANTATION-ASSOCIATED IMMUNE RESPONSES Publication number: 20170121404 Abstract: RGMb antagonists reduce undesirable immune responses associated with tissue or organ transplantation. Type: Application Filed: November 3, 2016 Publication date: May 4, 2017 Inventors: Everett Hurteau Meyer, Rosemarie H. Dekruyff, Panagiota Iliopoulou, Yuchiao Hsu, Magdiel Perez Cruz BLOCKADE OF TIM-1 FOR TREATING GRAFT-VERSUS-HOST DISEASE Publication number: 20170101471 Abstract: TIM1 antagonists reduce GVHD by symptom score and show statistically significant improved survival. Type: Application Filed: October 6, 2016 Publication date: April 13, 2017 Inventors: Panagiota Iliopoulou, Rosemarie H. Dekruyff, Everett Hurteau Meyer Antibody molecules to TIM-3 and uses thereof Patent number: 9605070 Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders. Type: Grant Filed: January 30, 2015 Date of Patent: March 28, 2017 Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., Children's Medical Center Corporation Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
Now to keep this certified letter to BODs moving along, and because there are so many damn puzzle pieces ....we must assume that the BODs likely are not up to speed on the patents out there that that simply cross over to PS Targeting and ask yourself this, when someone says it has no value, why in the hell are others like Bayer and Novartis speaking out about PS Targeting within their MOST RECENTLY filed patents ??
There is astronomical value ....that is why!
One letter is not enough, for me at least.....because I completely forget to ask if the new BODs have been given an expert review/ analysis on these other patents that Bayer Novartis Dana Farber etc have been filing?
I bet they have not ....and to play it safe it may be a good idea to send a 2nd certified letter focused on the PS Targeting IP which is up for sale and/or license and make damn sure all BODs realize they sit on the tip of an iceberg of new, daily new ....PS Targeting blitz of information that Stephen White fails miserably at trying to conclude it has not much value. Is Stephen White working next to Jeanette Bleecker it seems or maybe on the same payroll...
Read this prior post and I will start building off this post with all the Big Pharmas that make mention of Phosphatidylserine targeting and guess where the validation will be .....?